Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy

被引:9
作者
Elconin, JH
Roberts, KB
Rizzieri, DA
Vermont, C
Clough, RW
Kim, C
Dodge, RK
Prosnitz, LR
机构
[1] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Family Med, Div Biometry, Durham, NC 27710 USA
[4] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2000年 / 48卷 / 04期
关键词
Hodgkin's disease; combined modality therapy; large mediastinal adenopathy; radiation dose;
D O I
10.1016/S0360-3016(00)00695-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the effective dose of consolidation radiation in Hodgkin's disease (HD) patients with large mediastinal adenopathy (LMA) treated with combined modality therapy (CMT). Methods and Materials: Eighty-three HD patients with LMA receiving CMT between 1983 and 1997 at Duke University and Yale University mere identified. Patients underwent complete clinical staging. The staging breakdown was: IA, 4 patients; IB, 1 patient; IIA, 25 patients; IIB, 33 patients; IIIA, 3 patients; IIIB-6 patients; IVA, 2 patients; and IVB, 9 patients, All patients received induction chemotherapy (CT) as follows: MOPP/ABV(D), 31 patients; BCVPP, 15 patients; ABVD, 24 patients; MOPP, 3 patients; and other regimens, 10 patients, Following 6 cycles of CT, patients were restaged and classified as having either complete response (CR) or induction failure (IF). Post-CT gallium scans mere obtained in 52 patients. Patients with residual radiographic abnormalities were classified as having CR if they were gallium-negative and clinically well otherwise. Following induction CT, 78 patients had a CR, There were 5 Ifs. Consolidation irradiation was administered to all sites of initial involvement in patients who had achieved CR, RT dose varied. Patients were grouped into the following dose ranges: less than or equal to 20 Gy, 12 patients; 20-25 Gy, 24 patients; 25-30 Gy, 30 patients; greater than or equal to 30 Gy, 12 patients. Results: Overall survival and failure-free survival were both 76% at 10 Sears. Of the 78 CR patients, 15 failed. Patterns of failure were in-field alone, 8 patients; out of field alone, 2 patients; and combined, 5 patients. Failure patterns by RT dose were: less than or equal to 20 Cy, 0/12; 20-25 Gy, 7/24; 25-30 GS, 5/30; greater than or equal to 30 Gy, 3/11, There was no apparent correlation between RT dose and subsequent failure. Post chemotherapy gallium scans were helpful in predicting for failure. Of 48 patients in whom the gallium was negative after chemotherapy, there were 6 failures, compared with 9 failures among 30 patients in whom gallium was not done after chemotherapy (p = 0.066). Additionally, patients receiving adriamycin-based chemotherapy regimens had improved outcomes compared to those not receiving adriamycin (p = 0.03.) Conclusions: These retrospective data suggest that low-dose radiotherapy following CR achieved with induction chemotherapy (particularly when documented with gallium scanning) mag be as effective as higher doses for bulky HD at presentation. Phase III trials are necessary for confirmation of this hypothesis, (C) 2000 Elsevier Science Inc.
引用
收藏
页码:1097 / 1105
页数:9
相关论文
共 43 条
[11]   COMBINED MODALITY TREATMENT WITH LOW-DOSE RADIATION AND MOPP CHEMOTHERAPY FOR CHILDREN WITH HODGKINS-DISEASE [J].
DONALDSON, SS ;
LINK, MP .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (05) :742-749
[12]   2ND SOLID MALIGNANCIES AFTER COMBINED-MODALITY THERAPY FOR HODGKINS-DISEASE [J].
DORIA, R ;
HOLFORD, T ;
FARBER, LR ;
PROSNITZ, LR ;
COOPER, DL .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2016-2022
[13]   MEDIASTINAL IRRADIATION IN COMBINED MODALITY THERAPY FOR HODGKINS-DISEASE [J].
DOWLING, SW ;
PESCHEL, RE ;
PORTLOCK, CS ;
KRAMER, C ;
FARBER, LR ;
KNOWLTON, AH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (03) :543-546
[14]   Radiation following chemotherapy for mediastinal Hodgkin's disease: the outcome of various doses for bulky tumors [J].
Eisbruch, A ;
Kazerooni, EA ;
Sahijdak, WM ;
Francis, IR ;
Lichter, AS .
RADIOTHERAPY AND ONCOLOGY, 1998, 46 (01) :47-49
[15]   LOW-DOSE INVOLVED FIELD RADIATION AFTER CHEMOTHERAPY IN ADVANCED HODGKIN DISEASE - A SOUTHWEST-ONCOLOGY-GROUP RANDOMIZED STUDY [J].
FABIAN, CJ ;
MANSFIELD, CM ;
DAHLBERG, S ;
JONES, SE ;
MILLER, TP ;
VANSLYCK, E ;
GROZEA, PN ;
MORRISON, FS ;
COLTMAN, CA ;
FISHER, RI .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (11) :903-912
[16]   THEORETICAL CONSIDERATIONS IN COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPY FOR NEOPLASTIC DISEASE [J].
FISCHER, JJ ;
PAPAC, RJ .
JOURNAL OF THEORETICAL BIOLOGY, 1972, 37 (01) :105-&
[17]   FACTORS AFFECTING LATE MORTALITY FROM HEART-DISEASE AFTER TREATMENT OF HODGKINS-DISEASE [J].
HANCOCK, SL ;
TUCKER, MA ;
HOPPE, RT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (16) :1949-1955
[18]   THE MANAGEMENT OF BULKY MEDIASTINAL HODGKINS-DISEASE [J].
HOPPE, RT .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1989, 3 (02) :265-276
[19]  
HOPPE RT, 1982, BLOOD, V59, P455
[20]   EFFICACY AND TOXICITY OF MULTIAGENT CHEMOTHERAPY AND LOW-DOSE INVOLVED-FIELD RADIOTHERAPY IN CHILDREN AND ADOLESCENTS WITH HODGKINS-DISEASE [J].
HUDSON, MM ;
GREENWALD, C ;
THOMPSON, E ;
WILIMAS, J ;
MARINA, N ;
FAIRCLOUGH, D ;
KAUFFMAN, W ;
BOZEMAN, P ;
MACKERT, PW ;
ABROMOWITCH, M ;
JENKINS, J ;
BOULDEN, T ;
KUN, L .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :100-108